15 states agree to bankruptcy deal, Purdue to release documents

9 July 2021

Troubled drugmaker Purdue Pharma has stepped a little closer to emerging from bankruptcy, after securing the backing of 15 states for a settlement related to claims arising from the ongoing opioid crisis.

Purdue, developer of opioid-based analgesic Oxycontin (oxycodone), was forced to enter bankruptcy in 2019 as multiple jurisdictions in the USA filed suits seeking damages to help cover the cost of treating opioid addiction.

The company has been blamed for widening the use of opioids, through marketing practices which downplayed the risks of addiction.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK